Whether it might be beneficial to antagonize the egress of lymphocytes (e.g. with FTY720/Fingolimod)32 in draining lymph nodes of hormone receptor positive breast cancers remains to be experimentally proven e.g. in animal models or by studying the draining lymph node histology under conditions of therapeutic hormone ablation. The gene discussed is NR4A1; the disease is breast carcinoma.